Aspire Biopharma Seeks FDA Approval for Fast-Acting Sublingual Aspirin for Heart Attack Treatment

Aspire Biopharma has submitted a pre-IND meeting request to the US FDA for its fast-acting, high-dose sublingual aspirin formulation for suspected acute myocardial infarction (heart attack) treatment. The submission marks a significant milestone towards potential FDA approval. The company's clinical data shows its product begins to inhibit platelet aggregation in under two minutes, acting four to five times faster than chewed aspirin. Aspire's sublingual aspirin has demonstrated rapid pharmacological action, safety, and tolerability, potentially providing a more reliable treatment for heart attacks.